BlueWhale Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine and Jim Riley, PhD, Professor of Microbiology at Penn Medicine, reported that a first patient was dosed in a clinical trial at Penn using the company’s Synecta™ platform to streamline the manufacturing process for huCART19-IL18 cells in the treatment of hematologic cancers. Read more here.